Pomegra
London-based StandardX exits stealth with a £10M seed to build a particle-accelerator platform making rare isotopes for cancer medicine and fusion energy.
- StandardX raised a £10M seed led by Vsquared Ventures and East X Ventures, with firstminute Capital, UKI2S, Brevan Howard Macro Venture, and Geometry also participating.
- The company's accelerator-based "isotope refinery" is designed to produce multiple isotope types from a single platform, replacing a patchwork of reactor-dependent, single-isotope systems.
- Pilot isotope deliveries to a medical partner are targeted for 2027, with industrial-scale production planned from 2029.
Lead
StandardX, a London-based nuclear startup founded in 2025, emerged from stealth on September 23, 2026, with a £10 million seed round to build a particle-accelerator platform capable of producing multiple rare isotopes from a single industrial system. The round was led by deep tech investors Vsquared Ventures and East X Ventures, with firstminute Capital, the UK Innovation and Science Seed Fund (UKI2S), Brevan Howard Macro Venture, and Geometry also participating. Valuation was not disclosed.
What Does StandardX Actually Build?
The company's core product is what it calls an "isotope refinery" - a proprietary accelerator system designed to produce a broad portfolio of rare isotopes from a common industrial footprint. That contrasts with the current supply chain, which is built around legacy nuclear reactors, each typically configured to produce a single isotope type. When a reactor goes offline for maintenance or an unplanned shutdown, supplies of the isotopes it produces collapse with it.
The practical consequences are already being felt in hospitals. Shortages of medical-grade isotopes, particularly those used in diagnostic imaging and targeted radiotherapy, have periodically disrupted patient treatment. Technetium-99m, the most widely used diagnostic isotope globally, has experienced supply crises when specific reactor facilities were taken offline for months at a time. StandardX founders Richard Pearson (CEO) and Ross Allen (CTO) - both nuclear engineers with startup scaling experience - are betting that a unified accelerator platform can route around that single-point fragility.
Why Does the Isotope Supply Chain Keep Breaking?
The structural problem is that isotope production has historically been bundled with reactor operations at nuclear facilities originally built for weapons programs or power generation. Those facilities are aging, and the isotopes they produce cannot always be substituted with alternatives. Half-lives are short enough that long-distance shipping is often impractical, meaning when a facility in one country goes down, nearby hospitals cannot simply reorder from elsewhere.
Accelerator-based production - using cyclotrons or linear accelerators to bombard target materials with particles - is not a new concept in the isotope space. Several companies already operate single-product cyclotrons for specific medical isotopes. What StandardX claims differentiates its platform is breadth: one system configuration that can switch between isotope targets, serving multiple end markets from one facility without building separate infrastructure for each isotope type.
Fusion Energy as a Second Revenue Stream
Beyond medical supply, StandardX has signed commercial agreements with fusion energy developers to supply tritium, a hydrogen isotope required as fuel in most near-term fusion reactor designs. Tritium is exceptionally scarce in nature and currently produced almost entirely as a byproduct of fission reactors. As private fusion developers push toward commercial timelines - multiple firms are targeting demonstration plants in the late 2020s and early 2030s - their tritium needs will outpace what fission byproduct supply can deliver. StandardX's accelerator platform would produce tritium directly, converting a looming fuel scarcity problem into an addressable market.
What Comes Next for StandardX?
The £10M seed will fund three near-term objectives: expanding the engineering team, securing the company's first industrial site in London, and completing design and construction of its first full-scale accelerator refinery system. Pilot isotope production, with deliveries to a named medical research partner, is targeted for 2027. Commercial-scale output is planned from 2029.
The investor mix is notable. UKI2S participation typically follows a degree of government-side technical due diligence, while Brevan Howard Macro Venture - an arm of the macro hedge fund - brings a different risk appetite than pure deep tech funds. The combination suggests StandardX has cleared early credibility hurdles across both engineering and financial audiences.
The seed amount itself is modest relative to the capital intensity of what the company is building. Particle accelerators and the shielded industrial facilities required to operate them safely are expensive assets. The £10M buys the team and the design phase. The real test of the business model will come when StandardX goes back to the market for the considerably larger sum needed to build and commission a commercial-scale refinery.
Outlook
StandardX is entering a market where supply scarcity is a documented clinical problem, not a hypothetical one. Its dual-market strategy - serving both medical isotope buyers and fusion developers from a common platform - reduces dependence on any single sector's timeline. The critical tests ahead are engineering: whether one accelerator configuration can deliver commercially viable yields across a meaningful range of isotopes, and whether the 2027 pilot delivery milestone holds. If the refinery concept validates at pilot scale, the company would be positioned ahead of incumbent single-product accelerator operators - and ahead of a fusion industry that will need reliable tritium supply well before it can generate a single kilowatt of commercial power.
